{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.26","upperLimit":"0.26","value":"0.26"},{"groupId":"OG001","lowerLimit":"0.36","upperLimit":"0.37","value":"0.364"},{"groupId":"OG002","lowerLimit":"0.31","upperLimit":"0.31","value":"0.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 8 (or Day 15): Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.25","upperLimit":"0.25","value":"0.25"},{"groupId":"OG001","lowerLimit":"0.17","upperLimit":"0.24","value":"0.202"},{"groupId":"OG002","lowerLimit":"0.16","upperLimit":"0.44","value":"0.299"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 8 (or Day 15): 2 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.17","upperLimit":"0.19","value":"0.178"},{"groupId":"OG002","lowerLimit":"0.22","upperLimit":"0.22","value":"0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 8 (or Day 15): 6 hours post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Ratio to baseline was calculated dividing post-baseline measurements by the baseline measurement.","dispersionType":"Full Range","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"paramType":"MEAN","populationDescription":"The Pd population included all participants who received at least one dose of study intervention, had no clinically important protocol deviations or important events affecting Pd, and provide at least one measurable Pd endpoint post-dose. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number Analyzed\" signifies those participants who were evaluable for specified timepoints.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 pre-dose (Baseline), Pre-dose, 2 and 6 hours post-dose on Cycle 1 Day 8 (or Day 15) (each Cycle is of 28 days)","title":"Part A: Multiple Dose: Ratio to Baseline in Large Multifunctional Protease 7 (LMP7) Activity at Cycle 1 Day 8 (or Day 15)","type":"SECONDARY","unitOfMeasure":"ratio"}